Table 2.

HLA/Antigen complexes recognized by tumor-infiltrating lymphocytes (TIL) infused to RF-patients (n = 12)

Patient	HLA-A	HLA-B	HLA-C	HLA/antigen recognized
Positive TIL populations (n = 8)a
M88c	A*0201–0301	B*1302–4002	Cw*0602–0202	B*1302/NA88-A
M117	A*0201–2402	B*4402	Cw*0501–0202	A*0201/Melan-A/lage
				Cw*0501/lage
M134	A*0201	B*0801	Cw*0701	A*0201/Melan-A
170c	A*0201–0301	B*1402–4402	Cw*0501–0802	A*0201/Melan-A
180c	A*0201–0101	B*0702	Cw*0602–0702	A*0201/Melan-A
M182	A*0201	B*1801–4402	Cw*1203–0501	A*0201/Melan-A
M187	A*0301	B*1402–3503	Cw*0401–0802	Cw*0802/tyrosinase
M213c	A*0101–0301	B*3501	Cw*0303–0401	B*3501/MAGE-A2
Negative TIL populations (n = 4)b
M174c	A*2401–6801	B*1401–4402	Cw*0501–0802	–
M197c	A*0301	B*1801–0702	Cw*0702–1203	–
M177c	A*2402–2902	B*0702	Cw*0102–0802	–
M215c	A*2301–6801	B*5801	Cw*0202–0701	–

^aTIL populations that recognized at least one of the tested antigens in one HLA context

^bNo recognition of any HLA/antigen combination tested

^cMelanoma patients with only one invaded lymph node at treatment